National Cancer Institute investigating trial outliers to resurrect 'failed' drugs FierceBiotech The patient, who had advanced bladder cancer, experienced a complete response for 14 months to the drug combination everolimus (Afinitor) and pazopanib (Votrient) in a Phase I trial. In the trial, investigators recruited 9 patients with advanced solid ... |
